Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
855.09B
Market cap855.09B
Price-Earnings ratio
40.19
Price-Earnings ratio40.19
Dividend yield
0.68%
Dividend yield0.68%
Average volume
2.77M
Average volume2.77M
High today
$930.00
High today$930.00
Low today
$888.03
Low today$888.03
Open price
$923.95
Open price$923.95
Volume
4.23M
Volume4.23M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 855.09B, Eli Lilly(LLY) trades at $905.17. The stock has a price-to-earnings ratio of 40.19 and currently yields dividends of 67.5%.

During the trading session on 2026-04-15, Eli Lilly(LLY) shares reached a daily high of $930.00 and a low of $888.03. At a current price of $905.17, the stock is +1.9% higher than the low and still -2.7% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 4.23M, versus its average volume of 2.77M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

TipRanks 42m
Eli Lilly Stock Gets Another Buy Rating as Its Obesity Pill Hits the Market

BMO Capital Markets (BMO) is pounding the table on Eli Lilly’s (LLY) stock as the pharmaceutical giant launches its new weight-loss pill. Unlock hedge fund-lev...

Nasdaq 4h
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

Key Points Eli Lilly has a stronger weight-loss portfolio than Novo Nordisk. Eli Lilly also has a deep pipeline beyond its core therapeutic area. Novo Nordis...

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
TipRanks 8h
Eli Lilly asked for additional safety data on obesity pill, Reuters reports

The FDA has requested additional data from Eli Lilly (LLY) on potential liver injury linked to its newly approved obesity pill, along with post-marketing studie...

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

Simply Wall St 11h
Eli Lilly Adds CrossBridge ADCs To Broaden Oncology Growth Story

Eli Lilly (NYSE:LLY) is acquiring CrossBridge Bio to add next generation dual payload antibody drug conjugates to its oncology pipeline. The deal brings in ADC...

Eli Lilly Adds CrossBridge ADCs To Broaden Oncology Growth Story
Nasdaq 1d
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Seeking Alpha 1d
Eli Lilly to boost oncology pipeline with CrossBridge Bio buyout

CrossBridge Bio, a privately held biotech focused on developing cancer drugs, announced on Tuesday an agreement to be acquired by Eli Lilly (LLY) in an all-cash...

Eli Lilly to boost oncology pipeline with CrossBridge Bio buyout
Zacks 1d
The Zacks Analyst Blog Highlights Eli Lilly, Mastercard, Advanced Micro Devices and Stratus Properties

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...

The Zacks Analyst Blog Highlights Eli Lilly, Mastercard, Advanced Micro Devices and Stratus Properties
Simply Wall St 2d
Jaypirca Trial Win Highlights Eli Lilly’s Expanding Oncology Growth Story

Eli Lilly's Jaypirca (pirtobrutinib) achieved positive Phase 3 results in chronic lymphocytic leukemia and small lymphocytic lymphoma. The late stage trial sho...

Jaypirca Trial Win Highlights Eli Lilly’s Expanding Oncology Growth Story
TipRanks 2d
Novo Nordisk Partners with OpenAI — Is Eli Lilly the Real Target?

Denmark-based Novo Nordisk (NVO) is expanding beyond blockbuster drugs like Wegovy with a new partnership with OpenAI. The collaboration aims to use AI to speed...

TipRanks 2d
Eli Lilly Stock Gets Shot in the Arm from New Leukemia Drug

Eli Lilly (LLY) announced that it has made significant progress with a new leukemia drug, giving its stock a shot in the arm as a result. Unlock hedge fund-lev...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.